Novartis' trial results are impacting Royalty Pharma's investment decisions.

The entities involved

• Novartis →

  Swiss-American multinational pharmaceutical corporation

  • Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Sat 01:46
  • GSK and Novartis are identified as major pharmaceutical companies.Fri 02:16
• Royalty Pharma →

  biopharmaceutical company based in New York City

  • Visteon filed transaction details with the SEC and traded on the Nasdaq stock exchange on June 6, 2026.Sun 17:49
  • Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.Sun 02:34

Related events

• Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.Jun 7
• Novartis's trial setbacks are negatively affecting market sentiment and causing a stock decline.Sep 8
• The European Medicines Agency provided a positive opinion on a drug developed by Novartis.Sep 21
• Novartis sought Swissmedic regulatory approval for a drug, which was co-funded by Sida and introduced first in Ghana.Sep 15
• Partnership expands Novartis's oncology pipeline.Jun 24